TAGRISSO (osimertinib)

TAGRISSO is an EGFR TKI indicated as a monotherapy for:

First-line TAGRISSO

Baseline characteristics

TAGRISSO was studied across a broad population of patients with NSCLC in FLAURA.2

Baseline characteristics
Baseline characteristics